Could Indian heart stent study findings lead to price cuts?
This article was originally published in Clinica
Executive Summary
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.
You may also be interested in...
India's Caps On Cardiac Stent Pricing Angers Industry
India has brought cardiac stents under price controls after an advisory body to the health ministry contended there was “huge exploitation” of patients by the medical devices industry. The move drew strong criticism from industry which said the decision “does not bode well” for Prime Minister Narendra Modi’s stepped-up drive to attract foreign investment.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.